Core Viewpoint - Rosen Law Firm is reminding investors who purchased Caribou Biosciences, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Caribou securities is from July 14, 2023, to July 16, 2024, and the lead plaintiff deadline is February 24, 2025 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]. Group 3: Case Allegations - The lawsuit alleges that Caribou made false and misleading statements regarding the safety, efficacy, and commercial prospects of its product CB-010, particularly in comparison to approved therapies [4]. - It is claimed that Caribou was at significant risk of insufficient cash and liquidity to fund its operations, which could negatively impact its business [4]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, leading to investor damages when the truth was revealed [4].
CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit